NovAccess Global Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XSNX research report →
Companynovaccessglobal.com
NovAccess Global Inc. , a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. The company specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer.
- CEO
- Dwain K. Morris-Irvin
- IPO
- 1998
- Employees
- 3
- HQ
- Chesterland, OH, US
Price Chart
Valuation
- Market Cap
- $6.17K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -2.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 76.60%
- ROIC
- -0.01%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,769,187 · -177.93%
- EPS
- $-0.23 · -130.00%
- Op Income
- $-2,466,760
- FCF YoY
- 30.86%
Performance & Tape
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.80
- Avg Volume
- 1.07K
Get TickerSpark's AI analysis on XSNX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 17, 24 | Sumner David | other | 0 |
| May 31, 24 | CASSARINI JOHN | other | 0 |
| Mar 13, 23 | LAIRD NEIL J | other | 428,571 |
| Mar 13, 23 | CASSARINI JOHN | other | 857,143 |
| Mar 13, 23 | Anderson Jason Michael | other | 857,143 |
| Mar 18, 22 | Anderson Jason Michael | other | 0 |
| Mar 14, 22 | CASSARINI JOHN | other | 0 |
| Mar 14, 22 | Martin Daniel G. | other | 1,502,670 |
| Mar 14, 22 | Martin Daniel G. | other | 25,000 |
| Mar 14, 22 | Martin Daniel G. | other | 25,000 |
Our XSNX Coverage
We haven't published any research on XSNX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XSNX Report →